The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).
Jochen H. Lorch
Research Funding - Novartis
Naifa Busaidy
No relevant relationships to disclose
Daniel T Ruan
No relevant relationships to disclose
Pasi A. Janne
No relevant relationships to disclose
Sewanti Atul Limaye
No relevant relationships to disclose
Lori J. Wirth
No relevant relationships to disclose
Justine A. Barletta
No relevant relationships to disclose
Guilherme Rabinowits
No relevant relationships to disclose
Levi A. Garraway
Consultant or Advisory Role - Novartis
Eliezer Mendel Van Allen
No relevant relationships to disclose
Nikhil Wagle
No relevant relationships to disclose
Glenn J. Hanna
No relevant relationships to disclose
Krzysztof Misiukiewicz
No relevant relationships to disclose
Margaret Suda
No relevant relationships to disclose
Tyler C Haddad
No relevant relationships to disclose
Catherine E Devine
No relevant relationships to disclose
Amy Williams
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ghulam Warsi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marshall R. Posner
No relevant relationships to disclose
Robert I. Haddad
No relevant relationships to disclose